Arcadia Biosciences Announces End to Lawsuit Against Arista Cereal Technologies in New York
– Company’s global commercialization plans for GoodWheat™portfolio of innovative wheat ingredients remain on track –
“The vast majority of our GoodWheat™ portfolio as well as the overall target market for our wheat, soy and other nutrition and ingredient products is unaffected by our dispute with Arista. Our global commercialization plans for those products remain on track, with first sales expected this year,” said Raj Ketkar, president and CEO of Arcadia. “We remain committed to defending our intellectual property, however, and are still pursuing other avenues to protect our technology.”
Arcadia’s GoodWheat platform is a portfolio of novel non-GM wheat varieties including high fiber resistant starch (RS), reduced gluten and others. These varieties have been specially bred for unique value using Arcadia’s non-GM TILLING platform and can be delivered as organic or conventional wheat. For instance, Arcadia’s RS GoodWheat contains up to 94 percent amylose, the highest levels available, which has been proven to deliver significant health benefits. These same wheat varieties deliver total dietary fiber levels high enough to meet the US Food and Drug Administration’s “Good Source” of fiber or “High in Fiber” designations on consumer packaging.
In addition, Arcadia recently announced a major partnership with Ardent Mills, North America’s leading flour-milling and ingredient company, to develop and commercialize innovative wheat trait improvements. The first project focuses on extending the shelf life and improving the taste of whole wheat products for North American consumers, driving the increased consumption of fiber.
“The global wheat flour market is forecasted to reach
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are subject to risks and uncertainties that
could cause actual results to differ materially, and reported results
should not be considered as an indication of future performance. These
risks and uncertainties include, but are not limited to: Arcadia’s and
its partners’ and affiliates’ ability to develop commercial products
incorporating their traits, and complete the regulatory review process
for such products; Arcadia’s compliance with laws and regulations that
impact Arcadia’s business, and changes to such laws and regulations;
Arcadia’s future capital requirements and ability to satisfy its capital
needs; Arcadia’s ability to develop, enforce and defend its intellectual
property rights; and the other risks set forth in Arcadia’s filings with